Clinical evidence

Publications

Peer-reviewed research supporting the uPAR platform.

Curasight’s scientific foundation is supported by peer-reviewed publications of investigator-initiated trials covering uPAR biology, AE105 ligand development, preclinical radioligand therapy, first-in-human PET imaging and prospective clinical studies.

Selected publications (clinical)

Persson et al., Theranostics, 2015

First-in-human uPAR PET imaging with 64Cu-DOTA-AE105 in patients with breast, prostate and bladder cancer.

Skovgaard et al., Journal of Nuclear Medicine, 2017

Phase 1 evaluation of 68Ga-NOTA-AE105 uPAR PET in cancer patients.

Fosbøl et al., Journal of Nuclear Medicine, 2021

Prospective Phase 2 prostate cancer study linking uPAR PET uptake with Gleason score.

Carlsen et al., Journal of Nuclear Medicine, 2022

Clinical uPAR PET evidence in neuroendocrine neoplasms.

Risør et al., Journal of Nuclear Medicine, 2022

Clinical uPAR PET evidence in head and neck cancer.

Lawaetz et al., Diagnostics, 2023

Prospective Phase 2 study of uPAR PET/CT in regional lymph-node staging of oral and oropharyngeal squamous cell carcinoma. The study reported sensitivity insufficient to support uPAR PET/CT as a standalone regional nodal staging method.

Azam et al., EJNMMI Research, 2024

Prospective Phase 2 uPAR PET/MRI study in primary gliomas showing prognostic associations and high positivity in grade 4 gliomas.

Soldath et al., Journal of Nuclear Medicine, accepted

Prospective NSCLC study reporting prognostic information from preoperative uPAR PET/CT beyond FDG PET/CT.

Accepted

Explore the evidence

Clinical evidence

Human uPAR Validation

uPAR has moved from tissue biology to non-invasive imaging in patients.

Clinical evidence

Clinical Studies

A clinical program spanning imaging, prognosis, diagnosis and the first human delivery and dosimetry study supporting therapeutic development.

Science

Scientific Evidence

Evidence built from preclinical proof to human imaging and therapeutic development

Curasight A/S is a clinical-stage radiopharmaceutical company developing products targeting uPAR, a target associated with aggressive cancer biology and a cancer target expressed across solid tumor types. The portfolio is organized through uTRACE®, the imaging and diagnostic platform, and uTREAT®, the therapeutic development platform comprising clinical stage glioblastoma programs and a next-generation uPAR-targeting ligand designed for modular alpha and beta payloads for additional solid tumor types.

Investigational product statementTherapeutic product candidates within the uTRACE® and uTREAT® platform are investigational and they have currently not been approved for commercial use by any regulatory authority.

Forward-looking informationCertain information on this website may contain forward-looking statements regarding development plans, clinical milestones, regulatory activities, partnerships and other future events. Such statements involve risks and uncertainties, and actual outcomes may differ materially. Users should refer to Curasight’s latest market announcements and financial reports for current information.

Medical information statementInformation on this website is provided for general corporate and scientific information only and is not intended as medical advice. Patients should consult qualified healthcare professionals regarding diagnosis and treatment decisions.

+45 22 83 01 60 · info@curasight.com

Copyright 2026 © Curasight